SCTB35 injection: SCTB35 will be subcutaneously administered at a dose as specified
Rituximab: Intravenous Infusion
Lenalidomide: Oral Capsules
Study summary
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Age 18-80 years old
* Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria
* Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
* Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion
* A measurable or evaluable disease at the time of enrolment
* ECOG PS 0-2
* Adequate organ function and bone marrow function
* Expected survival ≥ 6 months
Exclusion Criteria:
* Documented refractoriness to lenalidomide.
* Have lenalidomide exposure within 12 months prior to randomization
Primary outcome measure(s)
Adverse Events — Up to approximately 3 years Treatment-emergent adverse events/serious adverse events/adverse events of special interest
Progression free survival (PFS) — Up to approximately 3 years Defined as the time from the date of randomization to the date of first documentation of progression disease (PD) or the date of death from any cause, whichever occurs first.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.